Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CPRX
STRONG BUYAPPROVECatalyst Pharmaceuticals, Inc. · Healthcare · United States · $3.9B · Avg Vol: $61M/d
Catalyst Pharmaceuticals exhibits classic high-quality compounder characteristics with a strong niche in rare neurological diseases, providing defensive growth that is uncorrelated to broader macro volatility. Their ability to maintain pricing power in specialized healthcare segments aligns perfectly with the 'Flywheel Growth in Aging Populations' theme, and they possess the capital discipline required to scale earnings without the leverage-dependent risks of the broader market.
COMPANY DESCRIPTION
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its primary product Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS). The company holds market exclusivity for its approved rare disease therapy, addressing a significant unmet medical need for a small patient population. It is a niche biopharmaceutical company specializing in treatments for rare neurological disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 214.2M | 398.2M | 491.7M | 589.0M | 40.1% | 597.0M | 636.2M | 717.9M | 10.4% |
| EPS | 0.80 | 0.67 | 1.38 | 1.75 | 29.8% | 1.73 | 2.04 | 2.05 | 8.1% |
| Shares | 105.3M | 107.1M | 120.9M | 122.5M | +16.4% | 122.4M | — | — | — |
| Debt | 3.9M | 3.6M | 3.2M | 2.8M | -10.6% | 2.7M | — | — | — |
| Equity | 300.4M | 387.9M | 727.6M | 954.3M | 47.0% | — | — | — | — |
| Op CF | 116.0M | 143.6M | 239.8M | 208.7M | 21.6% | 208.2M | — | — | — |
| Inv CF | 9.2M | -293.5M | -0.6M | -58.0K | — | — | — | — | — |
| Fin CF | 1.7M | -10.9M | 140.7M | -17.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc.(you) | $3.9B | 99 | STRONG BUY |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.1B | 99 | STRONG BUY |
| INVA | Innoviva, Inc. | $1.7B | 97 | STRONG BUY |
| HALO | Halozyme Therapeutics, Inc. | $8.9B | 90 | STRONG BUY |
| EXEL | Exelixis, Inc. | $13.8B | 97 | STRONG BUY |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.3B | 73 | BUY |
| TGTX | TG Therapeutics, Inc. | $8.5B | 83 | STRONG BUY |
| RIGL | Rigel Pharmaceuticals, Inc. | $716M | 98 | STRONG BUY |
| LGND | Ligand Pharmaceuticals Incorporated | $6.1B | 73 | BUY |
| KRYS | Krystal Biotech, Inc. | $11.0B | 84 | STRONG BUY |
Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%